Brian Powl - Jun 27, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Commercial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jun 27, 2022
Transactions value $
$0
Form type
4
Date filed
6/29/2022, 05:02 PM
Next filing
Feb 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +45K $0.00 45K Jun 27, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +70K $0.00 70K Jun 27, 2022 Common Stock 70K $26.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exempt grant of restricted stock units pursuant to the Issuer's Amended and Restated Inducement Equity Plan. 25% of the award will vest on July 1, 2023, and 25% of the remainder shall vest on July 1, 2024, July 1, 2025, and July 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.
F2 The option shall vest as to 25% of the underlying shares on June 27, 2023 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.